Patent classifications
A23V2250/1578
IMPROVED SUGAR-DEPLETED FRUIT OR VEGETABLE JUICE AND JUICE-RETAINING FRUIT OR VEGETABLE DERIVED MATTER, METHODS OF PRODUCING THE SAME AND THE USE THEREOF TO MAINTAIN HEALTH AND TO TREAT AND PREVENT MEDICAL AILMENTS
The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l Ca.sup.2+, (iii) at least about 1 g/l K.sup.+, and (iii) at least about 0.1 g/l Mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g. metabolic syndrome, diabetes mellitus type II, obesity, dyslipidemia, insulin resistance, hypertension and liver steatosis.
REDUCTION TREATMENT AGENT, REDUCTION COSMETIC, REDUCTION FOOD, AND METHOD FOR PRODUCING REDUCTION TREATMENT AGENT
A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.
REDUCTION TREATMENT AGENT, REDUCTION COSMETIC, REDUCTION FOOD, AND METHOD FOR PRODUCING REDUCTION TREATMENT AGENT
A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.
Method for treatment of fine dust-caused skin cell damage, reinforcement of skin barrier, anti-aging, and anti-inflammation
The present specification discloses a composition for external application to skin, containing a tea plant root extract as an active ingredient, for treatment of skin damage caused by fine dust, whereby the expression level of one or more selected from a group consisting of IL-36G (NM_019618), S100A7 (NM_002963), S100A8 (NM_002964) and XDH (NM_000379), which are genes in skin cells the expression level of which is affected by fine dust, is regulated to a normal level.
Method for treatment of fine dust-caused skin cell damage, reinforcement of skin barrier, anti-aging, and anti-inflammation
The present specification discloses a composition for external application to skin, containing a tea plant root extract as an active ingredient, for treatment of skin damage caused by fine dust, whereby the expression level of one or more selected from a group consisting of IL-36G (NM_019618), S100A7 (NM_002963), S100A8 (NM_002964) and XDH (NM_000379), which are genes in skin cells the expression level of which is affected by fine dust, is regulated to a normal level.
FILM COATING COMPOSITION AND METHODS OF MAKING AND USING THE SAME
A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided.
FILM COATING COMPOSITION AND METHODS OF MAKING AND USING THE SAME
A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided.
COMPOSITION FOR PREVENTING OR TREATING OBESITY CONTAINING ALPHA-LIPOIC ACID AND N-ACETYLCYSTEINE AS ACTIVE INGREDIENTS
The present invention provides a composition containing α-lipoic acid and N-acetylcysteine as active ingredients. The mixed composition of α-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing α-lipoic acid or N-acetylcysteine.
COMPOSITION FOR PREVENTING OR TREATING OBESITY CONTAINING ALPHA-LIPOIC ACID AND N-ACETYLCYSTEINE AS ACTIVE INGREDIENTS
The present invention provides a composition containing α-lipoic acid and N-acetylcysteine as active ingredients. The mixed composition of α-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing α-lipoic acid or N-acetylcysteine.
Beta-hydroxybutyrate mixed salt compositions and methods of use
Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.